What Is the Wegovy Equivalent to Mounjaro 10mg?

Why the trial data is the right place to start this comparison

Comparing doses across two different medicines only makes sense if you start with what each medicine actually achieved in clinical trials. Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist, it activates two separate gut-hormone pathways. Wegovy (semaglutide) targets the GLP-1 pathway alone. Because the biological mechanisms differ, you cannot assume that equal weight-loss percentages reflect equivalent doses, or that equivalent doses produce equal weight loss.

In the SURMOUNT-1 trial, published in the New England Journal of Medicine, tirzepatide at 15mg produced around 20–21% average body-weight reduction over 72 weeks. At 10mg (two steps below the maximum) results were meaningful but lower, consistent with the expectation that the higher maintenance doses carry the greatest effect. In the STEP 1 trial, semaglutide 2.4mg (Wegovy's standard maintenance dose) produced around 15% average reduction over 68 weeks. The direct head-to-head SURMOUNT-5 trial, also published in the New England Journal of Medicine in 2025, confirmed that tirzepatide produced greater average weight loss than semaglutide 2.4mg, a finding NICE cited in its appraisal of tirzepatide (TA1026) when noting that indirect comparisons favour tirzepatide. Those numbers are the foundation for thinking about dose equivalence: not just where you sit on the ladder, but what each rung is delivering.

Mapping Mounjaro 10mg onto Wegovy's schedule: what the ladders tell us

Mounjaro's UK titration runs: 2.5mg (starter) → 5mg → 7.5mg → 10mg → 12.5mg → 15mg. Wegovy's standard schedule runs: 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg. Mounjaro 10mg is the fourth step on a six-step ladder, comfortably into the therapeutic range but not yet at the maximum. Wegovy 1.7mg is the fourth step on a five-step ladder, and 2.4mg is maintenance. That positional similarity is the main reason prescribers and clinical guidance tend to place Mounjaro 10mg in the same broad category as Wegovy 1.7mg to 2.4mg when discussing treatment stage.

The table below maps the two schedules side by side so you can see how each dose sits relative to the full range. The figures are from the NHS tirzepatide page and the NHS semaglutide guidance. No weight-loss percentages appear next to intermediate doses because the trials were powered to report outcomes at the maintenance doses, not at each individual step.

If you are researching the Mounjaro-to-Wegovy dose conversion more broadly, that page works through the full ladder rather than focusing on the 10mg mark specifically.

Switching between medicines: what changes and what doesn't

If someone is established on Mounjaro 10mg and a prescriber is considering a switch to Wegovy, the question is not just which dose to land on, it is how to manage the transition safely. Our guide on switching from 10mg Mounjaro to Wegovy covers that process in detail, including how titration typically restarts from the lowest dose of the new medicine, because switching between GLP-1-class medicines is not the same as continuing on equivalent medication; the receptor profile differs and tolerance to one does not guarantee tolerance to the other. That is why the full Wegovy vs Mounjaro comparison matters: the differences in mechanism, side-effect profile and titration approach are clinically relevant, not just administrative.

A detail the numbers alone do not capture: someone who has been on Mounjaro 10mg for several months and is considering switching may have reached a plateau, may have experienced side effects, or may be moving between medicines for supply or clinical reasons. Each of those situations calls for a different approach. A prescriber needs to know all of it. Our clinical team (you can read about our approach on the clinical team profile) reviews each situation individually before any recommendation is made.

What this means practically if you are deciding between the two

The honest summary: at a comparable stage of treatment, Mounjaro 10mg and Wegovy 1.7mg to 2.4mg are broadly in the same treatment territory, but they are not interchangeable doses of the same medicine. If you are earlier in your Wegovy journey and want to understand what Wegovy 1mg is equivalent to in Mounjaro terms, that page explains how the two schedules align at that particular step. Mounjaro's dual-agonist mechanism means it has performed differently in trials, and the reason Mounjaro's doses are numerically higher than Wegovy's comes down to how the molecules are measured, not to Mounjaro being a stronger medicine at any given milligram figure.

For cost context, it is also worth looking at the Mounjaro vs Wegovy price comparison for the UK: Eli Lilly raised Mounjaro's list price substantially from September 2025, with the highest-dose pen rising from around £122 to around £330 per four-week pen, and typical private market prices since then have ranged roughly £149 to £375 per month depending on dose and provider, figures worth keeping in mind when weighing the options.

Which medicine suits you at which dose is a clinical decision. If you are ready to discuss it, you can start your free consultation and speak to our prescribers about what makes sense for your situation specifically.